Aurinia Pharmaceuticals Inc. (AUPH)
$16.36-1.15%Close
SELLRECOVERY · day 3
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $2.1B
- Beta
- 1.41
- P/E (TTM)
- 6.93
- Short % float
- 6.27%
- Days to cover
- 9.4
- SI change
- -7.7%
- 1W
- +4.27%
- 1M
- -0.30%
- vs SPY 1W
- +4.41%
- vs SPY 1M
- -2.81%
Industry peers
FMP comparable companies · ranked by market cap
- VERASELLVera Therapeutics, Inc.$1.9BCRISISQ 20$26.79-3.35%
- BHVNSELLBiohaven Ltd.$1.7BCRISISQ 16$11.42-3.30%
- TRAXSELLFirst Tracks Biotherapeutics Inc$1.1BQ 80$31.68-6.96%
- MLTXSELLMoonLake Immunotherapeutics$876MCRISISQ -1$10.41-2.53%
- ALMSSELLAlumis Inc.$810MCRISISQ 0$6.56-7.08%
- ATTOSELLAttovia Therapeutics, Inc.$633MQ -46$14.72+0.89%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on AUPH?
- LOPJLB’s latest quantitative signal on Aurinia Pharmaceuticals Inc. (AUPH) is SELL in a RECOVERY regime. Signals are updated daily.
- What market regime is AUPH in?
- Aurinia Pharmaceuticals Inc. (AUPH) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does Aurinia Pharmaceuticals Inc. (AUPH) do?
- Aurinia Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical company, specializing in the development and commercialization of innovative therapies. Its core mission is to address a variety of diseases for which current medical solutions are inadequate, serving patient populations across the United States and internationally. The company's flagship product is LUPKYNIS, an appro…